$307 Million is the total value of Abingworth LLP's 19 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCVX | Sell | VAXCYTE INC | $96,813,783 | -3.2% | 2,019,057 | -51.6% | 31.54% | -7.8% |
| VRNA | VERONA PHARMA PLCsponsored ads | $64,214,475 | +155.9% | 2,457,500 | 0.0% | 20.92% | +143.9% | |
| VERA | VERA THERAPEUTICS INCcl a | $57,280,470 | -9.2% | 2,960,231 | 0.0% | 18.66% | -13.5% | |
| HILLEVAX INC | $30,757,871 | -2.0% | 1,838,486 | 0.0% | 10.02% | -6.7% | ||
| ACET | ADICET BIO INC | $18,911,542 | -37.0% | 2,115,385 | 0.0% | 6.16% | -40.0% | |
| PHAT | PHATHOM PHARMACEUTICALS INC | $16,101,889 | +1.3% | 1,435,106 | 0.0% | 5.25% | -3.5% | |
| RPHM | RENEO PHARMACEUTICALS INC | $4,832,320 | -30.5% | 2,073,957 | 0.0% | 1.57% | -33.8% | |
| SIEN | SIENTRA INC | $3,397,386 | +217.2% | 1,673,589 | 0.0% | 1.11% | +202.5% | |
| JASPER THERAPEUTICS INC | $2,718,594 | -38.8% | 5,628,558 | 0.0% | 0.89% | -41.6% | ||
| SOLENO THERAPEUTICS INC | $2,378,982 | +18.5% | 1,201,506 | 0.0% | 0.78% | +13.0% | ||
| NCNA | NUCANA PLCsponsored adr | $2,200,000 | -35.3% | 3,333,333 | 0.0% | 0.72% | -38.3% | |
| EFFECTOR THERAPEUTICS INC | $2,063,865 | -24.4% | 4,822,114 | 0.0% | 0.67% | -28.0% | ||
| SPRB | SPRUCE BIOSCIENCES INC | $1,966,392 | -20.5% | 1,792,518 | 0.0% | 0.64% | -24.2% | |
| PRTK | PARATEK PHARMACEUTICALS INC | $1,946,915 | -27.2% | 1,041,131 | 0.0% | 0.63% | -30.7% | |
| CBAY | CYMABAY THERAPEUTICS INC | $821,596 | +79.8% | 131,036 | 0.0% | 0.27% | +71.8% | |
| EXICURE INC | $323,881 | -26.2% | 281,636 | 0.0% | 0.11% | -29.3% | ||
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $108,225 | -14.8% | 240,500 | 0.0% | 0.04% | -18.6% | |
| MTEM | MOLECULAR TEMPLATES INC | $66,000 | -56.0% | 200,000 | 0.0% | 0.02% | -56.9% | |
| OBSV | OBSEVA SA | $12,760 | -1.8% | 87,999 | 0.0% | 0.00% | 0.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Carlyle Group Inc. #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
| 13F-HR | 2023-02-10 |
| 4 | 2023-01-31 |
| 13F-HR | 2022-11-10 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.